Drug Profile
Research programme: aldosterone synthase inhibitors - Novartis
Alternative Names: SPP 2645; SPP2000 seriesLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Speedel Group
- Developer Novartis
- Class
- Mechanism of Action Aldosterone synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hyperaldosteronism
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hyperaldosteronism in USA (PO)
- 30 Mar 2010 Preclinical trials in Hyperaldosteronism in USA (PO)
- 10 Jul 2008 Speedel Group has been acquired by Novartis